AEMDHealthcare · Medical DevicesAEMD Stock Forecast: Aethlon Medical, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Aethlon Medical, Inc. hold a median 12-month price target of $3.25 — +387.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
AEMD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Aethlon Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (0): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Aethlon Medical, Inc. — and when they’d sell — is the membership.
AEMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AEMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +387.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | $1.50 |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 7 July 2025 | HC Wainwright & Co. | Assumes | Neutral | $1.50 |
| 10 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2022 | Maxim Group | Downgrade | Hold | — |
| 25 June 2021 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $9.00 |
| 1 June 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 8 Jan 2021 | Maxim Group | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AEMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Aethlon Medical, Inc. (AEMD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- 0.4×
Cheaper than 74% of US stocks
Cheaper than 89% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −142.9%
- Return on assets
- −66.6%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AEMD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AEMD appears on the weeks it earns a place.
Frequently asked questions about AEMD stock
What is the AEMD stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Aethlon Medical, Inc. have a median 12-month price target of $3.25, with estimates ranging from $1.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AEMD stock a buy right now?
Of the 2 analysts covering Aethlon Medical, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aethlon Medical, Inc. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AEMD?
As at 1 Aug 2026, Aethlon Medical, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
Will AEMD stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +387.4% from the last close, and Ticker Nerd's factor model ranks Aethlon Medical, Inc. 23 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AEMD stock forecast for 2030?
No analyst covering Aethlon Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $5 over the next 12 months.
How has AEMD stock performed over the past year?
Aethlon Medical, Inc. returned -94.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Aethlon Medical, Inc. do?
Aethlon Medical Inc. is a medical technology company focused on developing immunotherapeutic products for cancer and infectious disease.
About Aethlon Medical, Inc.
Aethlon Medical Inc. is a medical technology company focused on developing immunotherapeutic products for cancer and infectious disease. Its primary platform, the Aethlon Hemopurifier, is designed to reduce cancer-promoting exosomes and circulating viruses through extracorporeal blood filtration. The company’s work centers on clinical-stage solutions that address life- and organ-threatening conditions, with applications that intersect oncology, virology, and critical care medicine. Aethlon Medical serves the broader healthcare market by advancing device-based technologies intended for diagnostic and therapeutic use in severe diseases. Headquartered in San Diego, California, Aethlon Medical Inc. operates as a specialized developer of highly targeted medical treatments within the biotechnology and medical device sectors.
CEO Mr. James B. Frakes M.B.A. · 9 employees · United States · https://www.aethlonmedical.com